Hanmi Pharmaceuticals Co Ltd (128940):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9893)
◆英語タイトル:Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9893
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:72
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharma’s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea. Hanmi Pharma is headquartered in Seoul, South Korea.

Hanmi Pharmaceuticals Co Ltd (128940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Hanmi Pharma Enters into Licensing Agreement with Ajou University 23
Genentech to Enter into Licensing Agreement with Hanmi Pharma 24
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 25
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 26
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 27
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 28
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 29
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 30
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 31
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 32
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 33
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 35
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 36
Acquisition 37
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 37
Hanmi Pharmaceuticals Co Ltd – Key Competitors 38
Hanmi Pharmaceuticals Co Ltd – Key Employees 39
Hanmi Pharmaceuticals Co Ltd – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Product News 41
03/31/2017: Spectrum Pharmaceuticals Announces Presentation of Abstract on ROLONTIS (eflapegrastim) at the AACR 41
01/08/2018: Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials 42
Product Approvals 43
Oct 29, 2018: Athenex announces FDA allowance of Investigational New Drug Application of Eribulin ORA to begin clinical trials 43
Apr 19, 2018: Athenex Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma 44
Jul 05, 2017: Athenex Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA 45
Clinical Trials 46
Sep 24, 2018: Spectrum Pharmaceuticals announces release of updated Poziotinib data from MD Anderson phase 2 study in Non-Small Cell Lung Cancer Patients 46
Sep 13, 2018: Spectrum expands Phase ll trial of poziotinib for NSCLC 47
Sep 05, 2018: Spectrum Pharmaceuticals announces release of Poziotinib abstract as part of the IASLC 19th World Conference on Lung Cancer 48
Jun 04, 2018: Athenex Announces Poster Presentations at ASCO Annual Meeting 50
Apr 23, 2018: Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine 51
Apr 17, 2018: Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago 52
Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients 53
Feb 15, 2018: Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer 54
Jan 22, 2018: Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer 55
Jan 22, 2018: Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA (Ramucirumab) Combination Treatment in Gastric Cancer 56
Jan 16, 2018: Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol 57
Dec 27, 2017: Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel 58
Nov 20, 2017: ESMO Asia 2017: Athenex’s Oraxol (Oral Paclitaxel, Athenex) Can Achieve Similar Exposure to IV Paclitaxel in Cancer Patients 59
Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2 60
Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan 61
Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program 62
Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017 63
Aug 01, 2017: Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS (eflapegrastim), a Novel Long-Acting GCSF 65
Jul 19, 2017: Athenex, Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer 66
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor 67
Apr 04, 2017: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting 68
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations 69
Mar 28, 2017: Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer 70
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Hanmi Pharma Enters into Licensing Agreement with Ajou University 23
Genentech to Enter into Licensing Agreement with Hanmi Pharma 24
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 25
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 26
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 27
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 28
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 29
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 30
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 31
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 32
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 33
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 35
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 36
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 37
Hanmi Pharmaceuticals Co Ltd, Key Competitors 38
Hanmi Pharmaceuticals Co Ltd, Key Employees 39
Hanmi Pharmaceuticals Co Ltd, Other Locations 40
Hanmi Pharmaceuticals Co Ltd, Subsidiaries 40

List of Figures
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Hanmi Pharmaceuticals Co Ltd (128940):製薬・医療:M&Aディール及び事業提携情報(Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆